NeoTX Therapeutics Ltd. logo

NeoTX Therapeutics Ltd.

NeoTX Therapeutics Ltd. is based in Rehovot Israel and is a clinical stage immuno-oncology company. NeoTX was founded to bring safe and effective immunotherapies to cancer patients.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://neotx.com
Founded2015
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
2 Pekeris Street
Rehovot
Israel
Email
Contact Number
+972 3 912 5853

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/neotx-therapeutics-ltd” connections=”true” suffix=””]

In Oct 2016, NeoTX acquired worldwide further clinical development and commercialization of Active Biotech (NASDAQ OMX NORDIC: ACTI) investigational compound Naptomumab estafenatox (_ANYARAÓ) for cancer immunotherapy. The total deal value amounts to $71 Mn and is contingent upon achievement of clinical, regulatory and commercial milestones whereof Active Biotech will receive $250 000 as an initial payment upon signing. In addition, NeoTX will pay Active Biotech progressive, double-digit royalties on its net sales.

In Dec 2017, NeoTX raised over $8.7 Mn in Series B funding from investors including Starr Ventures, a fund led by former AIG CEO Hank Greenberg. Total funds raised since formation is nearly $18 Mn.

In Oct 2016, NeoTX raised over $8.8 Mn in Series A funding from Starr Ventures, a fund led by former AIG CEO Hank Greenberg.